The TOUCH program and natalizumab: Fundamental flaw in patient protection [version 2; referees: 2 approved, 1 approved with reservations]

by Jagannadha Avasarala
Published 2016-02-01

Title not available

by Jagannadha Avasarala
Published 2017-11-01

Title not available

by Jagannadha Avasarala
Published 2018-06-01

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

by Jagannadha Avasarala
Published 2017-10-01

DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?

by Jagannadha Avasarala
Published 2018-06-01

The TOUCH program and natalizumab: Fundamental flaw in patient protection [version 3; referees: 2 approved, 1 approved with reservations]

by Jagannadha Avasarala
Published 2016-05-01

Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?

by Jagannadha Avasarala, Naveen Parti
Published 2018-08-01